me-401
Small moleculeexperimental
Clinical trial activity
8 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02914938)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545112 ↗
Also known as
- me-401
- me-401
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05604417 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | Harvard University, MEI Pharma |
| NCT05209308 | Phase 2 | Nov 30, 2022 | Kyowa Hakko Kirin, MEI Pharma |
| NCT04745832 | Phase 3 | Apr 1, 2021 | Kyowa Kirin, MEI Pharma |
| NCT04517435 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Case Western Reserve University, University of Rochester |
| NCT04533581 | Phase 2 | Sep 17, 2020 | Kyowa Hakko Kirin |
| NCT03985189 | Phase 1 | Apr 29, 2019 | Kyowa Hakko Kirin |
| NCT03768505 | Phase 2 | Dec 15, 2018 | MEI Pharma |
| NCT02914938 | Phase 1 | Oct 1, 2016 | Clinipace LTD, Cornell University, MEI Pharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MEI Pharma | For profit | 5 | 4 | 3 | 2016 |
| Kyowa Hakko Kirin | For profit | 3 | 2 | 2 | 2019 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Clinipace LTD | For profit | 1 | 0 | 1 | 2016 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Kyowa Kirin | For profit | 1 | 0 | 1 | 2021 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2020 |
8 organizations
Page 1 / 1